Case report: Salvage capmatinib therapy in fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin.

Telisotuzumab vedotin is a -targeting antibody-drug conjugate that has demonstrated a good treatment response in patients with wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.